SCHEMBL3570075

SCHEMBL3570075

COc1ccccc1C(NC(=O)Nc1ccc(Cl)cc1)C(=O)NC1=CCC(=NN2CCCC2)C=C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 3/20 0.38
LMNA P02545 5/20 0.38
CNR1 P21554 3/20 0.38
ATM Q13315 1/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 3/20 0.38
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
CACNA1G O43497 1/20 0.35
S1PR1 P21453 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HPGD P15428 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
CCR3 P51677 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566653 0.91 CNR1 (0.36) MAPTNPC1RAB9ACNR1MEN1
SCHEMBL3560764 0.91 SMN1; SMN2 (0.36) MAPTNPC1RAB9ALMNACNR1
SCHEMBL3561031 0.89 CNR2 (0.35) MAPTLMNACNR1MEN1KMT2A
SCHEMBL3567223 0.89 CNR1 (0.34) MAPTRAB9ACNR1MEN1KMT2A
SCHEMBL3566171 0.89 CNR1 (0.34) RAB9ACNR1SMN1; SMN2ALDH1A1NPSR1
SCHEMBL3560271 0.88 CYP1A2 (0.35) MAPTLMNACNR1MEN1KMT2A
SCHEMBL3556133 0.88 FPR2 (0.40) MAPTNPC1LMNACNR1KMT2A
SCHEMBL3564975 0.87 LMNA (0.40) MAPTNPC1RAB9ALMNACNR1
SCHEMBL3563086 0.86 FPR2 (0.40) MAPTCNR1SMN1; SMN2ALDH1A1HTT
SCHEMBL3562894 0.83 SMN1; SMN2 (0.40) MAPTNPC1RAB9ALMNACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 MAPT 1933/4885NPC1 1325/4885RAB9A 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.